

# "Ketamine for Depression, but at What Cost? A Review of Ketamine's Neurotoxicity Effects from Preclinical and Human Studies"

Ross Silverstein, MD

Psychiatrist

Inova Fairfax Medical Campus - Affiliated Faculty

## Microsoft Teams

[Need help?](#)

[Join the meeting now](#)

Meeting ID: 237 799 384 398

Passcode: gy7Hz9yE

### Dial in by phone

[+1 571-307-5517,,570296992#](#) United

States, Washington

[Find a local number](#)

Phone conference ID: 570 296 992#

For organizers: [Meeting options](#) | [Reset dial-in PIN](#)

**Target audience:** Members of the medical staff all subspecialties, medical residents and students.

### Learning objectives:

- 1. Learn about Ketamine's neurotoxicity effects from preclinical and human studies.
- 2. Recognize the fundamental problems that off label use of Ketamine can pose
- 3. Understand important future research requirements

Article: The American Journal of Psychiatry, October 2025, Volume 182, Number 10 entitled: Ketamine for Depression, but at What Cost? A Review of Ketamine's Neurotoxicity Effects from Preclinical and Human Studies

**November 19, 2025**

**12:00 – 1:00 p.m.**

**To claim credit, text **PUDYOR** to 703.260.9391**

**Accreditation:** The Medical Society of Virginia is a member of the Southern States CME Collaborative, an ACCME Recognized Accreditor. Inova Health System Office of Continuing Medical Education is accredited by the Southern States CME Collaborative to provide continuing medical education for physicians.

**Credit designation:** The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 1.0 credit in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.